Efficacy of reducing phlegm with traditional Chinese medicine on non-small cell lung cancer: a Meta-analysis

Abstract

Abstract:

AIM: To systematically evaluate the efficacy of reducing phlegm with traditional Chinese medicine on non-small cell lung cancer. METHODS: We retrieved randomized controlled trials of efficacy of reducing phlegm with traditional Chinese medicine on non-small cell lung cancer from database of CNKI, WANFANG, VIP, PubMed that published since 2000. Three hundred and twenty-four patients treated by reducing phlegm with traditional Chinese medicine and chemotherapy were included in the experimental group; while another 323 patients treated by sole chemotherapy were included in the control group. All patients were selected then according to the including and excluding standard so as to evaluate the quality of literature. Experimental results were analyzed by STATA11.0 statistics software. RESULTS:A total of 647 cases of non-small cell lung cancer patients were included, with 324 cases in the experimental group and 323 cases in the control group. Phlegm reducing therapy presented elevated effective rate (RR=1.48, 95%CI=1.24 to 1.77, P<0.001); improved life quality (RR=1.92,95%CI=1.51 to 2.45, P<0.001); and better immunity (MD=0.36，95%CI=0.23 to 0.50, P<0.001). CONCLUSION: Compared with conventional medicine, reducing phlegm with traditional Chinese medicine exhibit better effect on non-small cell lung cancer.

Key words: reducing phlegm with traditional Chinese medicine, non-small cell lung cance, immunity, living quality, Meta-analysis

CLC Number:

R734

RONG Guoyi, WANG Shumei, TANG Mo. Efficacy of reducing phlegm with traditional Chinese medicine on non-small cell lung cancer: a Meta-analysis[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(7): 787-794.

References

［1］Perlikos F, Harrington KJ, Syrigos KN. Key molecular mechanisms in lung cancer invasion and metastasis:A comprehensive review［J］. Critical Rev Oncol Hematol,2013, 81(1): 1-11.
［2］Siegel RL, Miller KD, Jemal A. Cancer statistics，2015［J］.CA Cancer J Clin，2015，65(1):5-29.
［3］Siegel R, Naishadham D, Jemal A. Cancer statistics,2013［J］. CA Cancer J Clin, 2013, 63(1): 11-30.
［4］WHO. WHO handbook forreporting results of cancer treatment［M］. Geneva, Switzerland:World Health Organaization,1979.
［5］Yates JW, Chalmer B, Mckegney FP. Evaluation of patients with advanced cancerusing the karnofsky perfomance status［J］. Cancer, 1980, 45: 2220-2223.
［6］师瑞卿, 刘瑞娟. 扶正化痰法联合GP方案化疗治疗晚期非小细胞肺癌的临床疗效评价［J］.陕西中医杂志, 2015, 36(8): 986-988.
［7］张华堂, 方灿途, 黄振炎. 健脾养阴、化痰祛瘀法联合GP方案治疗中晚期非小细胞肺癌的临床观察［J］. 湖北中医杂志, 2008, 30(8): 11-13．
［8］步许海. 益气补肺、化痰散结类中药配合西药治疗中晚期非小细胞肺癌临床研究［J］. 亚太传统医药, 2016, 12(2): 111-112．
［9］李猛. 益气化痰法治疗中晚期非小细胞肺癌的临床观察［J］. 河北中医药学报, 2007, 22(1): 12-14.
［10］黄健飞，郭勇. 益气化痰方对晚期非小细胞肺癌患者化疗的疗效、不良反应及生存质量的影响［J］. 中华中医药学刊, 2015, 33(10): 2509-2511.
［11］杨新妹，徐玉芬，宋斌斌. 益气化痰方联合化疗对晚期非小细胞肺癌患者临床疗效、不良反应以及生存质量的影响［J］. 中华中医药学刊, 2016, 34(5): 1037-1039.
［12］张红, 陈州华. 益气活血化痰通络法治疗晚期非小细胞肺癌临床观察［J］. 中国中医急症, 2009, 18(10): 1587-1597.
［13］陈学彰，王艳杰，田华琴. 益气除痰法结合化疗治疗中晚期非小细胞肺癌的临床疗效观察［J］. 中国医药指南，2012，10(19): 332－333．
［14］纪国义. 益气除痰法与化疗联合治疗中晚期非小细胞肺癌的临床观察［J］. 中国继续医药教育，2012，7(25): 210－212．
［15］李向晖. 中西医结合治疗中晚期非小细胞肺癌的临床观察［J］.新中医，2015，47(7): 129-131.
［16］支修益，姜格宁. 早期原发性肺癌诊断和治疗进展［J］. 中国医学前沿杂志，2015，7(2):1-5．
［17］林洪生，李道瑞. 生存质量与中医肿瘤疗效评价［J］. 癌症进展杂志，2007，5(3): 249-251．
［18］姚嘉麟，杨铭，李嘉旗. 基于复杂系统熵网络的刘嘉湘诊治肺癌经验数据挖掘［J］. 上海中医药杂志，2016，50(3): 12-17．
［19］郑红刚，花宝金. 朴炳奎辨治肺癌学术思想与经验探析［J］. 中医杂志，2010，51(4): 304-306．
［20］邬晓东，姜丽娟. 周岱翰教授论治支气管肺癌临证经验特色举要［J］. 新中医，2014，46(12): 27-29．

[1]	MA Guangli, ZHANG Jing. Application of quantitative pharmacology in vaccine research and de-velopment: overview and prospect [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 315-322.
[2]	HUANG Xiaoming, DU Ye, LIN Shaoming, SHEN Guanle. Exploratory study of the influence of respiratory microbiology on the efficacy of PD-1 inhibitors monotherapy for patients with advanced non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 66-74.
[3]	YE Hongbo, SONG Yangyang, XUE Ling, RUI Jianzhong. Meropenem population pharmacokinetic model for the Chinese elderly established by model-based META analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 984-990.
[4]	ZHANG Kexin, JIA Wenjing, CUI Jiawen, AO Luyao, ZHOU Fang, WANG Guangji, LIU Jiali. Advances in the research and clinical application of the third generation EGFR TKIs in the treatment of non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1016-1030.
[5]	PEI Qinghua, SUN Jianli. Research progress of Osimertinib acquired resistance [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(1): 105-112.
[6]	YU Zhaolei, BAI Jianling, YU Hao, ZHAO Yang. Development of tools for clinical trial information retrieval and Meta-analysis based on R-Shiny: Taking non-small cell lung cancer as an example [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 984-991.
[7]	WEI Weitian, CHEN Sheng, WANG Liang, ZENG Jian. Breviscapine induced the apoptosis of non-small cell lung cancer A549 cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(6): 618-624.
[8]	CHEN Wenjun, RUAN Zourong, XIANG Xiaoqiang. Development and application progress of physiologically based pharmacokinetic modeling and its combined use with other modeling methods [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(3): 299-305.
[9]	LI Lujin, DING Junjie, LIU Dongyang, WANG Xipei, DENG Chenhui, JI Shangmin, CHEN Wenjun, MA Guangli, WANG Kun, SHENG Yucheng, XU Ling, PEI Qi, CHEN Yuancheng, CHEN Rui, SHI Jun, LI Gailing, WANG Yaning, WANG Yuzhu, XIE Haitang, ZHOU Tianyan, FANG Yi, ZHANG Jing, JIAO Zheng, HU Bei, ZHENG Qingshan. General considerations of model-based meta-analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(11): 1250-1267.
[10]	WANG Haili, GONG Tianxiao, ZHOU Shixia, MEI Jiazhuan, ZHANG Zhongmian. Efficacy and safety of third-line treatment with mesylate apatinib in patients with advanced non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(5): 567-572.
[11]	YANG Ke, LI Junling, DU Bin, TIAN Zhongqiu, JING Xiujuan. Single-arm,one-center, exploratory clinical trial of albumin-bound paclitaxel second and more line therapy for advanced non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(11): 1281-1286.
[12]	MENG Qiuhua, TIAN Jing, QIN Feizhang, QIN Yang, DONG Min. Research progress of PD-1/PD-L1 pathway inhibitor in the immunotherapy of digestive system neoplasm [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(8): 942-948.
[13]	WANG Haixia, LIU Xingan, HOU Jiyuan, GONG Zhe, SHAN Guoyong. Influence of genetic variation of KDR on clinical outcomes of advanced NSCLC treated by first line bevacizumab regimens [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(7): 802-808.
[14]	SHAO Yaojun, ZHENG Tong,WANG Yanqiu,LIU Ling,YAO Yingshui. Nimodipine combined with flunarizine for preventing and treating migraine: A Meta-analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(6): 646-652.
[15]	LI Weiwen, LI Yuan, SUN Lei, HUANG Gongcai, ZHAO Zhongwei. Synergistic effect of Addie injection on pemetrexed combined with nedaplatin in the treatment of advanced non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(3): 325-328.